ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,212.20
0.10%
S&P ASX All Technology
3,444.90
0.35%
Brent Oil
70.905
-0.06%
US Dollar vs AUD
1.45006
-0.06%
Bitcoin
65,492.52
0.47%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Biohaven Ltd (BHVN)

  7. Biohaven Ltd (BHVN) News

BHVN

Biohaven (BHVN)

Biohaven Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:BHVN
DateTimeSourceHeadlineSymbolCompany
24/09/202420:15IH Market NewsVisa Faces Monopoly Lawsuit; Meta Introduces Celebrity Voices for Chatbot; Stellantis on the Hunt for New CEONYSE:BHVNBiohaven Ltd
23/09/202423:11Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
23/09/202421:30PR Newswire (US)Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)NYSE:BHVNBiohaven Ltd
21/09/202409:09PR Newswire (US)Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar AtaxiaNYSE:BHVNBiohaven Ltd
17/08/202406:35Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
17/08/202406:31Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
17/08/202406:25Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
17/08/202406:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:BHVNBiohaven Ltd
10/08/202406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
09/08/202406:17Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
09/08/202406:05PR Newswire (US)Biohaven Reports Second Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
29/05/202421:30PR Newswire (US)Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D DayNYSE:BHVNBiohaven Ltd
29/05/202421:15PR Newswire (US)Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsNYSE:BHVNBiohaven Ltd
18/05/202406:42Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
18/05/202406:41Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NYSE:BHVNBiohaven Ltd
10/05/202406:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:BHVNBiohaven Ltd
10/05/202406:14Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
10/05/202406:05PR Newswire (US)Biohaven Reports First Quarter 2024 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
23/04/202406:05PR Newswire (US)Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesNYSE:BHVNBiohaven Ltd
18/04/202406:05PR Newswire (US)Biohaven Announces Proposed Public Offering of Common SharesNYSE:BHVNBiohaven Ltd
13/04/202423:00PR Newswire (US)Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business UpdatesNYSE:BHVNBiohaven Ltd
01/03/202408:16Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
01/03/202408:05PR Newswire (US)Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
08/01/202423:30Edgar (US Regulatory)Form 8-K - Current reportNYSE:BHVNBiohaven Ltd
08/01/202423:30PR Newswire (US)Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and OncoloNYSE:BHVNBiohaven Ltd
02/01/202423:00PR Newswire (US)Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:BHVNBiohaven Ltd
02/12/202308:30PR Newswire (US)Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual MeetingNYSE:BHVNBiohaven Ltd
15/11/202308:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BHVNBiohaven Ltd
15/11/202308:05PR Newswire (US)Biohaven Reports Third Quarter 2023 Financial Results and Recent Business DevelopmentsNYSE:BHVNBiohaven Ltd
16/10/202322:00PR Newswire (US)Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®NYSE:BHVNBiohaven Ltd
 Showing the most relevant articles for your search:NYSE:BHVN

Your Recent History

USOTC
FSSTF
CI Morningstar Canada Mo... (GM)
TG
A19P25
Brambles Finance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved